Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion in Cash
Eli Lilly announces the acquisition of Ventyx Biosciences for $1.2 billion in an all-cash deal. This marks Lilly's first major transaction of 2026, expanding its pipeline into autoimmune and inflammatory diseases.
Insights:
Eli Lilly and Company , the world's most valuable drugmaker, has announced its acquisition of Ventyx Biosciences for $1.2 billion in an all-cash transaction. This strategic move marks Eli Lilly's first major acquisition of 2026, further enhancing its already dominant position in the pharmaceutical industry. The deal, which was announced on Wednesday, January 7, 2026, involves Eli Lilly purchasing all outstanding shares of Ventyx Biosciences at $14 per share, representing approximately a 2% premium over the previous day's closing price.
